Related Experiment Video
Updated: Dec 17, 2025
05:37
Partial Lobular Hepatectomy: A Surgical Model for Morphologic Liver Regeneration
Published on: May 31, 2018
12.6K
Advances in biomarker development in acetaminophen toxicity.
Laura P James1, Mitchell R McGill2, Dean W Roberts1
1Department of Pediatrics, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, United States.
Advances in Clinical Chemistry
|June 23, 2020
Summary
Diagnosing acetaminophen liver injury is difficult without specific biomarkers. This chapter reviews new candidate biomarkers for acetaminophen-induced acute liver injury, aiding diagnosis and predicting toxicity.
Area of Science:
- Hepatology
- Toxicology
- Biomarker Discovery
Background:
- Acetaminophen liver injury is a leading cause of acute liver injury in the US.
- Current diagnostic methods lack validated and specific biomarkers for acetaminophen-induced acute liver injury.
- Early and accurate diagnosis is crucial for effective patient management.
Purpose of the Study:
- To provide an overview of recent advancements in candidate biomarker evaluation for acetaminophen-induced acute liver injury.
- To explore the relationship between potential biomarkers and the mechanisms of acetaminophen toxicity.
- To assess the utility of these biomarkers in confirming diagnosis and predicting toxicity progression.
Main Methods:
- Review of current literature on acetaminophen toxicity.
- Evaluation of emerging biomarkers for acetaminophen-induced acute liver injury.
- Analysis of biomarker-toxicity relationships and diagnostic potential.
Main Results:
- Several candidate biomarkers are under investigation for acetaminophen-induced acute liver injury.
- Biomarkers show potential in elucidating acetaminophen toxicity mechanisms.
- Promising biomarkers may aid in diagnosis and prediction of evolving liver injury.
Conclusions:
- Development of specific biomarkers is critical for improving acetaminophen liver injury diagnosis.
- Emerging biomarkers offer hope for earlier detection and better management of acetaminophen toxicity.
- Further research is needed to validate these biomarkers for clinical use.
More Related Videos
Related Concept Videos
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
115
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
115
01:22Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation
671
Glutathione, a tripeptide made up of glutamate, cysteine, and glycine, is a critical player in the detoxification of drugs and xenobiotics via a process known as glutathione conjugation or mercapturic acid formation. This phase II biotransformation reaction involves the covalent binding of glutathione to a drug or its metabolite, enhancing the compound's water solubility and enabling its excretion.
Several distinctive characteristics distinguish glutathione conjugation from other phase II...
Several distinctive characteristics distinguish glutathione conjugation from other phase II...
671
01:24Phase II Reactions: Acetylation Reactions
636
Acetylation, a phase II biotransformation reaction, introduces an acetyl group to drugs or their metabolites. Acetyltransferase enzymes facilitate this reaction, which resembles α-amino acid conjugation due to the addition of a functional group to the drug molecule.
The substrates for acetylation are typically drugs or their metabolites with an amino, sulfonamide, or hydrazine functional group. Acetylation can occur at several points in the drug molecule, including primary, secondary, and...
The substrates for acetylation are typically drugs or their metabolites with an amino, sulfonamide, or hydrazine functional group. Acetylation can occur at several points in the drug molecule, including primary, secondary, and...
636
01:20Measurement of Bioavailability: Pharmacodynamic Methods
130
Pharmacodynamic methods provide insights into a drug's effects on physiological processes over time and play a crucial role in understanding bioavailability and therapeutic efficacy. These methods can be broadly classified into acute pharmacological and therapeutic response approaches, each with distinct mechanisms and applications.The acute pharmacological response method directly correlates a drug's physiological effects, such as ECG or pupil diameter changes, to its time course in the body.
130
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
121
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
121
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
133
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
133